Q-omics provides the consensus-scored MIR1262 profile across patient tissues and cancer cell-line models. MIR1262 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR1262 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, MIR1262 RNA expression shows 12,193 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, HNSC, and TGCT as cancer lineages where MIR1262 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1262 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1262 survival associations across molecular data types. MIR1262 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1262 RNA expression–survival associations across cancer types. High MIR1262 expression shows unfavorable associations in SKCM, ACC, HNSC, CHOL and PCPG, but favorable associations in KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR1262 RNA expression.
This table summarizes MIR1262 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1262. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1262 shows lower tumor expression in KIRP and higher tumor expression in HNSC and KICH. The HNSC box plot shows higher MIR1262 RNA expression in tumor versus normal tissue (log2 FC = +0.170, t-test p = .010).
This table shows molecular features associated with MIR1262 in patient tissues and cancer cell lines. In patient samples, MIR1262 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
